Louisiana First to Offer Statewide Access to Epic’s MyChart Central
Epic says MyChart Central simplifies the user experience with a single sign-in and a united view across organizations
Read More
How Much do People with Employer Plans Spend Out-of-Pocket on Cost-Sharing??
This Peterson-KFF Health System Tracker chart collection examines trends in employee spending on deductibles, copayments, and coinsurance from 2012 to 2023 using a sample of health benefit claims for individuals under 65.
KFF Health News’ ‘What the Health?’: Starting To Feel the Shutdown’s Bite
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Starting To Feel the Shutdown’s Bite
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
US Healthcare Providers and Payers Accelerate AI Adoption for Financial Gains
Bain/KLAS survey shows 70 percent of providers and 80 percent of payers have an AI strategy either in place or in development
With $4.7B Akero Acquisition, Novo Nordisk Maps Out Broader Strategy in MASH and Beyond
Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in the emerging class of FGF21 analogs for the fatty liver disease MASH. The deal comes months after Novo’s internal FGF21 drug candidate failed a Phase 2 trial. The post With $4.7B Akero Acquisition, Novo Nordisk Maps…
With $4.7B Akero Acquisition, Novo Nordisk Maps Out Broader Strategy in MASH and Beyond
Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in the emerging class of FGF21 analogs for the fatty liver disease MASH. The deal comes months after Novo’s internal FGF21 drug candidate failed a Phase 2 trial. The post With $4.7B Akero Acquisition, Novo Nordisk Maps…
Lynn Rapsilber on Nurse Practitioners
There are a lot of nurse practitioners in the US–over 400,000 (compared to around 900,000 MDs & DOs), and we are training 40,000 a year. But how they are going to be used is not entirely clear. Lynn Rapsilber is an NP whose organization, the National Nurse Practitioner Entrepreneur Network, is working to help her…
From Margins to Mainstream: How Amplification May Be Giving Misinformation New Reach
Efforts to correct misinformation can unintentionally amplify it by increasing engagement, repetition, and visibility. During times of low trust, even debunked claims can erode confidence in health institutions. Communicators can limit amplification by focusing on verified facts, using prebunking and strategic debunking, and strengthening trust with credible messengers.
Impacts of Recent Federal and State Actions on Natural Disaster Preparedness and Response on Health
As climate change-related disasters worsen, the federal government’s shrinking of emergency and disaster preparedness support to state and local governments may leave millions of people vulnerable and unable to recover from natural disasters.